StratifiDen™

Dengue Fever

A global fast-emerging pandemic-prone viral disease

20,000
world-36479_1280.png
400,000,000

people have Dengue infections every year

500,000

people progressed on to develop severe Dengue and required hospitalization

hospitalized severe Dengue patients die from the disease

US$17.7 Billion

worth of socioeconomic cost

icon-01.png
3.9 Billion

world population

at risk of Dengue

infections every year

icon_Artboard 2.png
2 Billion

more people at risk of Dengue infection by 2080

Challenge

 The challenge in the clinical management of Dengue is how to accurately predict which patients will develop severe Dengue in the early phase of the disease to determine whether the patient needs to be hospitalized.
 

user.png
first-aid-kit.png
hospital.png
group-of-people-in-a-formation.png
dollar (1).png

Suspected Dengue case

Patient visits the hospital to seek treatment

Patient gets hospitalized if they exhibit 1 or more warning signs

Warning signs include:

  • Abdominal pain or tenderness

  • Persistent vomiting

  • Clinical fluid accumulation

  • Mucosal bleed

  • Lethargy or restlessness 

  • Liver enlargment >2 cm

  • Increase in HCT concurrent with rapid decrease in platelet count

Unnecessary hospitalization as over 50% of hospitalized Dengue patients do not develop severe Dengue

Increase in unnecessary healthcare expenses and burden to healthcare system

Solution

 With the introduction of StratifiDen™, a severe Dengue prediction test, we are able to determine the risk of severe Dengue development.
 

user.png
first-aid-kit.png
Picture5.jpg

Suspected Dengue case

Patient visits the hospital to seek treatment

Use of StratifiDen test to predict risk of severe Dengue 

hospital.png
heartbeat.png

Patient gets hospitalized if predicted to develop severe Dengue

More focused medical attention and aggressive supportive treatment on patients with severe Dengue 

home.png

Patient gets triaged to outpatient care if predicted not to develop severe Dengue

user.png

Avoid unnecessary hospitalization

dollar.png

Reduced unnecessary healthcare expenses

How it works

StratifiCare™ has discovered a panel of biomarkers that are able to determine the risk of severe Dengue.

Through simple laboratory analysis, information on the outcome of the disease can now be determined.

1

2

3

4

test-tube.png

Collect patient's blood sample

assay.png

Perform assay using StratifiDen™ to detect presence of biomarkers

computer.png

Quantify analytes by colour intensity

clipboard.png

Determine if patient will go on to develop severe Dengue

Benefits

favicon final.png

Reduction of hospitalization burden

StratifiDen™ reduces hospitalization burden by 67%, which helps to prevent overwhelming of the healthcare system.

coin.png

Cost Savings

Save on unnecessary hospitalization expenses for patients if condition can be managed as an outpatient case.

happiness.png

Ease of anxiety

Patients and their family members can be informed in advance of disease outcome.

heart(blue).png

Focused Medical Care

Patients at risk of developing severe Dengue can be given appropriate attention and treatment.

checked.png

Easy Adoption

Technology is based on well-established assay platform commonly used in hospitals. No additional training is required for technicians.

seo-and-web.png

Assay Accuracy

90% sensitivity and 97% specificity.*

Based on pre-clinical studies.

StratifiDen_edited.jpg

Enquire on StratifiDen™ now